{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:26:47Z","timestamp":1791563207580,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HA22C0012"],"award-info":[{"award-number":["HA22C0012"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejca.2023.113386","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T11:10:11Z","timestamp":1697281811000},"page":"113386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB\/II study (KCSG BR18-16)"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-906X","authenticated-orcid":false,"given":"Se Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-8738","authenticated-orcid":false,"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-3240","authenticated-orcid":false,"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-2764","authenticated-orcid":false,"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-8666","authenticated-orcid":false,"given":"Kyoung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-584X","authenticated-orcid":false,"given":"In Sil","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2464-7920","authenticated-orcid":false,"given":"Kyong Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-0552","authenticated-orcid":false,"given":"Hee-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-7268","authenticated-orcid":false,"given":"So Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-3620","authenticated-orcid":false,"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113386_bib1","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2023.113386_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113386_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and Hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113386_bib4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.113386_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13058-016-0724-2","article-title":"Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups","volume":"18","author":"Netanely","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2023.113386_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13058-019-1218-9","article-title":"Immune gene expression profiling reveals heterogeneity in luminal breast tumors","volume":"21","author":"Zhu","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2023.113386_bib7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.113386_bib8","first-page":"401","article-title":"Mesenchymal\u2013epithelial transition and tumor vascular remodeling in eribulin chemotherapy for breast cancer","volume":"38","author":"Kashiwagi","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2023.113386_bib9","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.21873\/anticanres.14317","article-title":"Validation of systemic and local tumour immune response to eribulin chemotherapy in the treatment of breast cancer","volume":"40","author":"Kashiwagi","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2023.113386_bib10","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2020.3524","article-title":"Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor\u2013positive, ERBB2-negative metastatic breast cancer: a randomized clinical trial","volume":"6","author":"Tolaney","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.113386_bib11","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-20-4726","article-title":"Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase Ib\/II StudyPhase","volume":"27","author":"Tolaney","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113386_bib12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejca.2021.02.028","article-title":"Pembrolizumab plus eribulin in hormone-receptor\u2013positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): an open-label, multicentre, single-arm, phase II trial","volume":"148","author":"P\u00e9rez-Garc\u00eda","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113386_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13058-016-0717-1","article-title":"Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation","volume":"18","author":"Wen","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2023.113386_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0030063","article-title":"Population stratification of a common APOBEC gene deletion polymorphism","volume":"3","author":"Kidd","year":"2007","journal-title":"PLOS Genet"},{"key":"10.1016\/j.ejca.2023.113386_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10549-020-05811-2","article-title":"Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer","volume":"183","author":"Kim","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2023.113386_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ejca.2023.113386_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113386_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113386_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113386_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25769-z","article-title":"Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer","volume":"12","author":"Keenan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2023.113386_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.11809","article-title":"Validation of progression-free survival rate at 6 months and objective response for estimating overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis","volume":"3","author":"Kok","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923006883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923006883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:16Z","timestamp":1760733676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923006883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":21,"alternative-id":["S0959804923006883"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113386","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB\/II study (KCSG BR18-16)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113386"}}